Organon & Co. (NYSE:OGN) Shares Acquired by EMC Capital Management

EMC Capital Management lifted its holdings in Organon & Co. (NYSE:OGN) by 153.8% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,831 shares of the company’s stock after purchasing an additional 8,381 shares during the period. EMC Capital Management’s holdings in Organon & Co. were worth $260,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in OGN. Norges Bank acquired a new position in shares of Organon & Co. in the fourth quarter worth $26,321,000. Sound Shore Management Inc. CT grew its stake in Organon & Co. by 35.2% during the 4th quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock worth $67,415,000 after purchasing an additional 1,216,522 shares in the last quarter. Allianz Asset Management GmbH grew its stake in Organon & Co. by 156.5% during the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock worth $27,406,000 after purchasing an additional 1,159,519 shares in the last quarter. Kahn Brothers Group Inc. increased its holdings in Organon & Co. by 3,242.4% during the 1st quarter. Kahn Brothers Group Inc. now owns 1,180,204 shares of the company’s stock worth $22,188,000 after purchasing an additional 1,144,894 shares during the period. Finally, LSV Asset Management raised its position in Organon & Co. by 34.0% in the 1st quarter. LSV Asset Management now owns 4,488,828 shares of the company’s stock valued at $84,390,000 after purchasing an additional 1,139,249 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 3.4 %

Shares of OGN traded down $0.74 during mid-day trading on Friday, reaching $20.91. The company’s stock had a trading volume of 2,064,104 shares, compared to its average volume of 2,247,578. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.08. The stock has a market cap of $5.38 billion, a PE ratio of 5.29, a price-to-earnings-growth ratio of 1.02 and a beta of 0.85. The company’s 50 day moving average is $20.89 and its 200 day moving average is $19.16.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The firm had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Equities analysts anticipate that Organon & Co. will post 4.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. The Goldman Sachs Group boosted their price objective on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler boosted their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.